Inicio>>Signaling Pathways>> Proteases>> ACE>>Leucylarginylproline

Leucylarginylproline

Catalog No.GC32520

La leucilarginilprolina es un inhibidor de la enzima convertidora de angiotensina (ECA) con una IC50 de 0,27 μM.

Products are for research use only. Not for human use. We do not sell to patients.

Leucylarginylproline Chemical Structure

Cas No.: 133943-59-6

Tamaño Precio Disponibilidad Cantidad
1mg
82,00 $
Disponible
5mg
331,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Leucylarginylproline is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 0.27μM.

Intravenous injection of Leucylarginylproline (30mg/kg) causes a decrease in the blood pressure. The maximum mean blood pressure reduction (about 15 mmHg) occurrs about 2 min after the injection[1]. Leucylarginylproline peptide reduces the blood pressure by about 15 mmHg at the fourth hour and shows a maximal reduction effect of about 35 mmHg at the eighth hour after oral administration[2].

[1]. Miyoshi S, et al. Structures and activity of angiotensin-converting enzyme inhibitors in an alpha-zein hydrolysate. Agric Biol Chem. 1991 May;55(5):1313-8. [2]. Chen TL, et al. Microencapsulation and modification of synthetic peptides of food proteins reduces the blood pressure of spontaneously hypertensive rats. J Agric Food Chem. 2003 Mar 12;51(6):1671-5.

Reseñas

Review for Leucylarginylproline

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Leucylarginylproline

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.